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PURPOSE 
Clinical and experimental investigations demonstrated that metformin, a widely used 
anti-diabetic drug, exhibits cardioprotective properties against myocardial infarction. 
Interestingly, metformin was previously shown to increase the expression of PGC-1α a 
key controller of energy metabolism in skeletal muscle, which is down-regulated in 
diabetic conditions.  We hypothesized that chronic treatment with metformin could 
protect the aged, diabetic heart against ischemia-reperfusion injury (IRI) by up-regulating 
PGC-1α and improving the impaired functionality of diabetic mitochondria. 
METHODS 
Following 4 weeks of metformin (300mg/kg) administered in the drinking water, 12 
month-old diabetic Goto Kakizaki and non-diabetic Wistar rat hearts were assigned for 
infarct measurement following 35min ischemia and 60min reperfusion or for electron 
microscopy (EM) and Western blotting (WB) investigations. 
RESULTS 
Metformin elicited a cardioprotective effect in both non-diabetic and diabetic hearts.  In 
contrast with the diabetic non-treated hearts, the diabetic hearts treated with metformin 
showed more organized and elongated mitochondria and demonstrated a significant 
increase in phosphorylated AMPK and in PGC-1α expression. 
CONCLUSIONS  
In summary these results show for the first time that chronic metformin treatment 
augments myocardial resistance to ischemia-reperfusion injury, by an alternative 
mechanism in addition to the lowering of blood glucose.  This consisted of a positive 
effect on mitochondrial structure possibly via a pathway involving AMPK activation and 
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PGC-1α. Thus, metformin prescribed chronically to patients may lead to a basal state of 
cardioprotection thereby potentially limiting the occurrence of myocardial damage by 
cardiovascular events.  
 
KEYWORDS:  
Ischemia –reperfusion injury, Cardioprotection, PGC-1α, Metformin.
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INTRODUCTION 
Cardiovascular disease, with its main consequence myocardial infarction, is a leading 
cause of debilitation and death in Westernized societies. Diabetes mellitus is a major risk 
factor for ischemic heart disease (IHD) [1]. Patients with diabetes and IHD experience 
worse clinical outcomes [2], suggesting that the diabetic heart may be more susceptible to 
ischemia-reperfusion injury (IRI). Given these observations, novel cardioprotective 
strategies are required to try and eliminate the increased cardiovascular risk in diabetic 
patients. The hyperglycaemic profile and the associated microvascular consequences of 
diabetes have been suggested to play an important role in increasing patient’s 
susceptibility to infarction [3]. 
Metformin, an oral anti-diabetic drug from the biguanide, insulin sensitizing class, 
has been suggested as a potential cardioprotective agent [4]. There are various 
mechanisms that have been suggested to play a role in metformin’s glucose-lowering 
effect, including inhibition of complex I of the mitochondrial respiratory chain [5], 
decreasing hepatic glucose production [6], increasing glucose uptake [7] and stimulation 
of adenosine monophosphate-activated protein kinase (AMPK) [8]. However, the 
cardioprotective effect exerted by metformin could be independent of its hypoglycaemic 
actions [9]. 
 AMPK, a serine-threonine kinase that can sense and restore energy 
homeostasis when a cell becomes deprived of energy, has been well documented as an 
important component in the pathway by which metformin produces its glucose lowering 
effects [8] however, more recent investigations have also implicated this kinase in the 
cardioprotective effect of this drug [10] . There have been numerous studies investigating 
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the action of metformin in an acute setting and it has been shown that metformin can 
reduce infarct size in both non-diabetic and diabetic hearts [11].  In comparison, there has 
been little experimental work investigating chronic effects of metformin, a scenario 
reflecting patients on metformin treatment in the clinic. In addition, it has been 
demonstrated that drugs may activate different pathways when given acutely versus 
chronically. [12-14].  
 Metformin has a plethora of effects on endogenous factors with roles in cellular 
survival; amongst them is Peroxisome Proliferator-Activated Receptor Gamma 
Coactivator-1α (PGC-1α) [15], a tissue-specific transcriptional co-activator which plays a 
key role in regulating energy metabolism [16]. PGC-1α is predominantly expressed in 
mitochondrial-rich tissues such as brown adipose tissue, skeletal muscle and the heart 
[16]. As PGC-1α plays a vital role in energy metabolism [16] and mitochondrial 
bioenergetic responses [17], it is suggested that this coactivator can interact with 
mitochondrial regulatory pathways [18] and possibly with factors involved in 
mitochondrial dynamics such as mitofusion-2 (Mfn-2) [18]. 
Interestingly, the diabetic status has been associated with a reduced level of PGC-
1α [19;20]; while metformin has been shown to increase the expression of PGC-1α in 
skeletal muscle possibly via AMPK activation [15]. Gundewar et al, 2009 showed that 
chronic low dose (125µg/kg) metformin administered after irreversible LAD ligation in 
normoglycaemic mice, exerts beneficial effects on cardiac function and survival in this 
heart failure model via an increase in AMPK activation and an increase in PGC-1α 
expression [21]. However, there is limited information regarding these effects in the 
diabetic heart and their role in the protection against IRI.  In addition to diabetes, age can 
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also contribute to the IRI damage [20;22]. Interestingly, Reznick et al 2007, compared 
AMPK activity in young (3 months) and old (28 months) rats and demonstrated an age-
associated decrease in AMPK activity and mitochondrial biogenesis [23]. Age related 
changes in metabolism and mitochondrial biogenesis, suggest PGC-1α as a potential 
target for anti-aging strategies [24;25].   
The aim of the present study was to investigate in aged, rat heart, whether chronic 
metformin treatment reduces myocardial infarct size through a mechanism independent 
of lowering blood glucose. We hypothesized that chronic metformin treatment could 
possibly activate AMPK and restore PGC-1α expression. Furthermore, that this 
restoration of PGC-1α could lead to improved mitochondrial biogenesis in these hearts 
and hence provide an enhanced capacity to be protected against an ischemic insult. 
 
METHODS 
Animals  
Male Goto-Kakizaki (GK) rats (a mild, non-obese diabetic model [26] obtained from 
Taconic (Denmark), were kept in house until they reached 12 months of age; they 
received humane care in accordance with the United Kingdom Animal (Scientific 
Procedures) Act of 1986. Male Wistar rats (normoglycaemic) were obtained from Charles 
River UK Limited (Margate, UK) and kept in house until they also reached 12 months of 
age. 
Materials 
Metformin (Sigma, UK) was dissolved in water to give final concentration of 300mg/kg 
per treated rat as described further. Antibodies for phospho-α-AMPK (Thr 172), total α-
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AMPK, phospho-Akt (Ser 473) and total Akt were obtained from Cell Signaling (Hitchin, 
Kent). Antibodies for PGC-1α and mitofusion-2 (Mfn-2) from Abcam, UK. Qproteome 
nuclear protein kit used for nuclear fractionation of proteins was purchased from Qiagen. 
All other reagents were of standard analytical grade.  HbA1c, a measure of glycated 
haemoglobin, was tested using an A1C now+ test kit (Bayer, UK). Overnight fasting 
blood glucose was measured using Accu-chek system (Roche). 
 
Treatments  
Animals were singly housed and randomly assigned to receive either 300mg/kg/day 
metformin sweetened with a non-caloric sweetener in drinking water, or sweetener alone 
in drinking water for 4 weeks. The metformin was sweetened to mask its metallic taste 
[27] otherwise animals tended to have a reduced water intake. A pilot study was 
performed on 6 animals, whereby the drinking rate was monitored for 7 days in order to 
estimate the water consumption. Throughout the treatment the drinking rate was 
monitored every 2 days and then the amount of powdered metformin was adjusted to 
ensure each rat received a dose of 300mg/kg/day. The animals were randomly selected 
for IRI followed by infarct measurements or for Western blot analysis and electron 
microcopy studies. 
There were 4 experimental groups: Wistar and Goto Kakizaki control groups 
which received only the sweetener in the drinking water and Wistar and Goto Kakizaki 
treated groups which received metformin added with the sweetener in the drinking water. 
  
Langendorff perfused heart studies 
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For determination of infarct size, GK and Wistar rats were anesthetized with sodium 
pentobarbital (55 mg/kg I.P.) and heparin (300 IU). The hearts were rapidly excised and 
quickly mounted onto a Langendorff constant pressure perfusion system (ADInstruments, 
Chalgrove, UK) as described by Bell et al, 2011 [28]. The hearts were perfused via the 
aorta with modified Krebs-Henseleit bicarbonate buffer (KH) (mM: NaCl 118.5, 
NaHCO3 25.0, KCl 4.8, MgSO4 1.2, KH2PO4 1.2, CaCl2 1.7 and glucose 11.0), gassed 
with 95% O2/5% CO2 and heated to 37°C to maintain a pH of 7.4. Regional ischemia was 
induced for 35min by occluding the left anterior descending coronary artery (LAD), 
followed by 60min reperfusion [29]induced by the release of the occluding suture. Then 
the suture was permanently tied around LAD, and 0.25% Evans blue dye was infused 
through the aorta to delineate the risk zone, with the myocardium not at risk staining 
blue. Infarct size was measured by incubating the heart sliced transversely in 
triphenyltetrazolium chloride solution (TTC; 1% in phosphate buffer). TTC reacts with 
intracellular dehydrogenases forming a red precipitate in the living cells leaving the dead 
tissue off white. The slices were then transferred to 10% formalin overnight and then 
scanned into the computer for analysis. Image J was used to calculate the volume of 
infarction within the risk zone (I/R %). 
 
 Measuring the heart function 
 A latex, fluid filled balloon was inserted into the left ventricle through an incision in the 
left atrial appendage and inflated to a pressure of 8-10mmHg. Perfusion pressure was set 
at 70mmHg, left ventricular end developed pressure (LVEDP) and heart rates (HR) were 
permanently monitored and the rate pressure product (RPP) calculated. Coronary flow 
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was also collected at regular intervals throughout the investigation. A thermo probe 
inserted into the pulmonary artery continuously monitored temperature. 
 
Electron microscopy and Western blot sample collection 
In these investigations, three groups of animals, all 12 months of age, were used: a) 
control GK rats receiving only the sweetener; b) treated GK rats which received 
metformin and c) non-treated Wistar rats (normoglycaemic controls), (n=4 in each 
group), The animals were anesthetized with sodium pentobarbital (55 mg/kg I.P.) and 
heparin (300 IU). Hearts were harvested and samples from the left ventricle were 
collected in the electron microscopy fixative buffer, or snap frozen in liquid nitrogen for 
Western blot analysis. 
 
Electron microscopy analysis  
To analyze mitochondrial appearance the heart samples were blindly coded and 4 
ultrathin sections were viewed with a Joel 1010 transition electron microscope (Joel Ltd, 
Warwickshire, UK.). At least 6 electron micrographs of each section were viewed and 
photos of the interfibrilar mitochondria taken and analyzed. Subsequently the codes were 
revealed and the photos investigated for patterns amongst groups. 
 
Western blot analysis  
The tissue was homogenized in PBS buffer (pH to 7.4) containing Calbiochem protease 
inhibitor cocktail III EDTA free (1:1000), Sigma phosphatase inhibitor cocktail III 
(1:100) and EDTA 1mM. Protein content was then determined using bicinchoninic acid 
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(BCA) protein assay reagent (Sigma, UK) and protein levels corrected accordingly to 
ensure equal protein loading. Equal volumes of Laemmli lysis buffer (Sigma, UK) 
containing 5% β-mercaptoethanol were added and the samples were denatured by heating 
to 80-90°C for 10 minutes. Sodium-dodecylsulphate (SDS) polyacrylamide gel 
electrophoresis (PAGE) was used to analyze the protein expression and activation of our 
proteins of interest using the Mini Protean III system (BioRad, UK) and incubation with 
appropriate primary antibodies. The membranes were then probed with a horseradish 
peroxidase (HRP) linked secondary antibody, either anti-mouse or anti-rabbit (1:1000) 
dependent on the primary source. Protein bands were visualized by enhanced 
chemiluminescence (ECL, Amersham, UK) and quantified by densitometry using Image 
J software.  
For detection of PGC-1α in different sub cellular compartments, nuclear and 
cytoplasmic extracts from GK and metformin treated GK rat hearts were prepared using a 
nuclear/cytosol fractionation kit (Qiagen-Qproteome nuclear protein kit) according to the 
manufacturer’s instructions. Equal amounts of nuclear or cytoplasmic protein were 
subjected to western blotting of PGC-1α, and the fractions verified using nuclear TATA 
binding protein and cytosolic α-tubulin. 
 
Statistical Analysis  
Data were analysed by either one-way ANOVA followed by Bonferroni’s multiple 
comparison test, students t-test or repeated measures ANOVA using GraphPad Prism 5.0 
(GraphPad Software Inc, San Diego, California, USA). The choice of test is noted in the 
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figure legend.  A p-value <0.05 was considered to be statistically significant. Values are 
presented as means ± standard error mean (SEM). 
 
RESULTS 
Metformin treatment and glucose level 
As metformin has insulin-sensitizing effects and therefore the ability to lower blood 
glucose, the diabetic status of the GK and Wistar rats was monitored throughout the 4 
week study. Blood glucose, haemoglobin A1C (HbA1c) and body mass were measured 
prior to the study, then at 2 weeks and at 4 weeks. Metformin reduced blood glucose and 
HbA1c by 33.4% and 23.8% (P<0.005), respectively following 4 weeks of treatment in 
GK rats. However, Metformin did not reduce blood glucose in normoglycaemic Wistar 
rats (P=ns).  As expected, as a side effect of metformin treatment, GK rats receiving the 
drug showed a 7.4% (P<0.005) decrease in body weight. In the control groups no 
significant changes were recorded for these parameters. Data is shown in tables 1 and 2. 
Mean plasma insulin levels were not assessed in this study, however in accordance with 
Portha et al, 1991, the glycaemic status we report is consistent with impaired insulin 
secretion and resistance previously reported in the GK model of type 2 diabetes [30].  
 
Chronic metformin treatment decreases infarct size in both the diabetic and non-
diabetic heart 
Metformin given chronically for 4 weeks at 300mg/kg/day significantly reduced infarct 
size in diabetic rat hearts by 65.4% compared to non-treated GK rats (I/R %; 16.6% ± 2.0 
vs 47.8 ± 2.0 P<0.0005). Data were expressed as infarct to risk volume percentage 
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(Figure 1a). There was no difference regarding the area at risk (AAR) between the 
groups (56.2% ± 3.5 vs 58.1% ± 1.6). The functional parameters were also monitored 
throughout the experimental protocol. It appears that metformin treatment had no 
significant effect on either RPP or coronary flow (Figure 1b and c) in this model. This 
treatment also significantly reduced infarct size in normoglycaemic Wistar rat hearts (I/R 
%; 40.8 ± 4 .5 vs 58.9 ± 3.5 P<0.05) (Figure 2a), however the protection was blunted 
compared to the effect seen in the GK rat.  Metformin treatment in Wistar rat hearts also 
had no significant effect on either RPP or coronary flow (Figure 2b and c) in this model. 
 
Mitochondrial appearance is improved after chronic metformin treatment in the 
diabetic heart 
 To investigate the hypothesis that chronic metformin treatment is associated with 
improved mitochondrial structure and function, in the first instance we used electron 
microscopy to visualise the shape, structure and number of mitochondria in the hearts of 
the GK rats treated or not with metformin for 4 weeks. The mitochondria in the untreated 
hyperglycaemic GK hearts appeared unorganised and more spherical in shape (Figure 
3a).  Interestingly, following metformin treatment, the mitochondria appear more 
organised and elongated (Figure 3b), resembling those in the Wistar normoglycaemic 
heart (Figure 3c). 
 
AMPK but not Akt is activated in the diabetic heart following chronic metformin 
treatment   
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To assess the effect of metformin treatment in diabetic rat hearts we measured the 
baseline levels of AMPK and Akt phosphorylation following 4 weeks treatment. The 
reduction in infarct size was mirrored by a significant increase in the phosphorylation of 
AMPK at baseline, prior to ischemia (1.4±0.1 vs 0.9±0.1 a.u., P<0.05) with no change 
noted in total AMPK protein levels (Figure 4a). In contrast, phosphorylated Akt was 
unchanged following 4 weeks of metformin treatment (3.9 ± 0.4 vs 4.0 ± 0.2 a.u. P= ns) 
(Figure 4b). 
 
An increase in PGC-1 and Mfn 2 levels are seen in the diabetic heart following 
metformin treatment. 
 It has been documented that PGC-1α’s expression is down regulated in type 2 diabetes 
[19;20] and that metformin can increase the expression of PGC-1α in skeletal muscle 
[15]. Indeed, we saw a down regulation of PGC-1α protein in the diabetic rat hearts in 
comparison to the non-diabetic hearts (0.38 ± 0.1 vs 0.54 ± 0.1, P<0.0005), however 
following metformin treatment, the expression of PGC-1α was significantly restored 
(0.38 ± 0.1 vs 0.47 ±0.1 P<0.005) (Figure 5a). Of note, our Western blot analysis of 
PGC-1α revealed two protein bands at 90 and 113kDa similar to that in the study by 
Aquilano et al, 2010 [31]. They explained the double banding by potential splicing or by 
a post translational change such as acetylation or phosphorylation of the protein and 
performed extensive investigations to convincingly demonstrate that both bands are in 
fact PGC-1α [31]. 
We have also investigated if metformin treatment and the subsequent up 
regulation of PGC-1α affected the protein expression levels of Mfn-2. Diabetic status had 
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no significant effect on the levels of Mfn-2 at baseline (2.6 ± 0.2, Wistar vs 2.3 ± 0.2, GK 
a.u. P=NS); however, metformin treatment significantly increased the expression of Mfn-
2 in diabetic hearts to a level greater than that seen in the normoglycaemic Wistar hearts 
(2.6 ± 0.2 vs 3.3±0.1 a.u. , P<0.005) (Figure 5b). 
PGC-1α is a dynamic molecule that is known to migrate between different 
subcellular compartments of the cell to exert different effects [32]; therefore we sought to 
investigate if metformin treatment had an impact on this process. Following subcellular 
fractionation we found that the nuclear PGC-1α expression decreased following 
metformin treatment compared to untreated GK hearts (Figure 6). Surprisingly, the 
cytosolic fraction showed no difference in PGC-1α expression. Moreover, the cytosolic 
fractions appear on the blots as a single band compared to the double band seen in the 
total cell extract (Figure 5) and in the nuclear fraction (Figure 6). 
 
Discussion 
Metformin has been demonstrated to be cardioprotective in different experimental models 
of ischemia-reperfusion injury. By using a model which corroborates 2 co-morbidities 
(diabetes and age) the data presented in this paper enhance the information regarding this 
protection. Investigating the effect of chronic metformin treatment in 12 month old 
diabetic and non-diabetic rats, we have demonstrated that this drug widely prescribed to 
type II diabetic patients reduced infarct size in both diabetic and non-diabetic hearts, 
albeit to a lesser extent in the latter group. This suggests that the cardioprotection elicited 
by metformin in the diabetic heart is not entirely glucose dependent. The cardioprotection 
was associated with an improvement in mitochondrial arrangement and appearance, 
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AMPK phosphorylation and increased myocardial expression of PGC-1α and Mfn-2 in 
the diabetic heart.   
To our knowledge, this is the first time that (i) PGC-1α protein expression has 
been shown to be down-regulated in aged, diabetic rat myocardial tissue (ii) that in the 
aged, diabetic rat heart metformin chronically restores PGC-1α expression and that (iii) 
Mfn-2 could potentially play a role in metformin induced protection in this set up. 
Although we do not show any direct evidence, it is possible that metformin through 
phosphorylation of AMPK can up-regulate and provide an increased platform for 
activation of PGC-1α via either phosphorylation or deacetylation [33].  This increase in 
activity may then act downstream on the mitofusion protein Mfn-2 which contributes to 
improved mitochondrial biogenesis and renders the diabetic heart less prone to damage 
by IRI. 
 Plasma levels of metformin were not measured in this study; the dose given 
of 300mg/kg/day may appear high compared to the dose of 20mg/kg/day given to 
patients in the clinical setting. However, investigations have shown that even when 
given as 50mg/kg/day, the plasma level of metformin in mouse blood was almost 
undetectable after 24 hours [34]. There have been numerous data suggesting that 
300mg/kg/day in rodent studies is required to mirror the effect of 50µM of 
metformin in human plasma  [35;36]. On the contrary, other studies have suggested 
this dose to be approximately 3-5 times greater than daily dose recommended in 
humans [37]. However, it has be shown that, for metformin to exert its 
hypoglycaemic actions in diabetic rats, relatively high doses are required to reach 
plasma concentrations similar to those found in humans[38;39]. 
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 There has been a great interest in the molecular mechanisms of metformin’s 
cardioprotection following the release of clinical data suggesting that diabetic patients 
receiving metformin had less cardiovascular complications than patients on other 
treatments [40]. However, the molecular mechanisms underlying this protection seem to 
be complex and not fully understood yet. The majority of experimental studies have been 
performed in an acute setting, either administrating metformin for a short period before 
an ischemic insult [10] or following ischemia [41] in a post-conditioning fashion. 
However, if a long term treatment can potentially lower the incidence of cardiovascular 
events, prevention is often preferable to cure. Therefore investigations into the 
mechanisms underlying why long term treatment with metformin proves beneficial is 
essential. The majority of experimental evidence in the acute setting thus far shows a 
strong involvement via AMPK activation [42;43]. Our study as well shows that chronic 
metformin treatment causes long term activation of AMPK by phosphorylation. This is 
supported by a clinical study by Musi et al, 2002 [44] demonstrating that AMPK is still 
activated in skeletal muscle following 10 weeks of oral metformin treatment in type II 
diabetic patients [44]. In contrast, Haunton, 2011, could not find an increase in the 
phosphorylation of AMPK [45] after only 2 weeks of treatment in normoglycaemic rat 
heart, using the same treatment. Interestingly, at a higher dose of metformin an increase 
in AMPK phosphorylation is seen [45], suggesting that perhaps the cardioprotective 
benefits of metformin are time and/or dose-dependent [46]. When interpreting our 
data, it is important to have in mind that the in vivo administration of a drug such 
as metformin will lead to a plethora of downstream effects that will promote cell 
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survival in both the heart and other body systems. However our reseach is focused 
on investigating the pathway involving AMPK and PGC-1α in the heart [47]. 
In addition, some authors support the hypothesis of an AMPK-independent effect 
of metformin [48]. This variability in results may be caused by the use of different 
experimental models such as normoglycaemic, genetically modified or chemically 
induced diabetic animals. In this respect, we consider the old Goto Kakizaki rat model 
used in this study, to more closely mirror a non-obese middle aged diabetic patient.  
 Previous studies have shown that acute metformin treatment given at the time of 
reperfusion can activate the RISK pathway kinase Akt via phosphorylation [41]. This 
activation led to a PI3K-dependent inhibition of the mitochondrial permeability transition 
pore (mPTP) and therefore reduced infarct size in this model of IRI [41]. However, 
chronic treatments may not manifest the same outcomes as acute drug administration due 
to inhibitory feedback regulation mechanisms [12]. This may explain why we did not find 
an increased level of Akt phosphorylation following chronic metformin treatment. 
 Firstly, we observed for the first time an increase of the PGC-1α in the diabetic 
heart following chronic metformin treatment. Previously the same effect was noted in 
skeletal muscle [15]. PGC-1α is extensively documented as a key regulator of energy 
metabolism [16], its expression is finely regulated to meet the energy demands of cellular 
systems [49]. There are numerous mechanisms that can control the expression levels of 
PGC-1α; however, these are dependent on the tissue and the circumstance. Interestingly, 
research investigating the regulation of PGC-1α in skeletal muscle showed that increasing 
the levels of the energy sensor AMPK by pharmacological activation, either by 5-
aminoimidazole-4-carboxamide-1-β-d-ribofuranoside (AICAR) [50] or metformin [15] 
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caused an enhanced activation of mitochondrial biogenesis via increasing PGC-1α 
expression.  Yet, the mechanisms by which increasing AMPK activity can lead to a 
subsequent increase in PGC-1α expression are still under investigation. Our study 
replicates this scenario: following administration of metformin for 4 weeks we recorded 
an increase in activation of AMPK and a subsequent increase in the expression levels of 
PGC-1α in the heart, an effect similar to that previously seen in skeletal muscle.  
Up regulation of PGC-1α expression can provide a platform for post translational 
modifications to occur. A dynamic shift in localisation can take place in response to a 
change in the energy status of the cell, with the main pool localised in the cytoplasm 
rapidly modified by phosphorylation, de/acetylation, ubiquination, methylation or 
GlcNacylation [49].  Subsequently PGC-1α can be both activated and transported into a 
different cellular location, for example into the nucleus to encode target genes, or remains 
in an inactive form in the cytoplasm, all depending on the cellular demands [32].  
We sought to assess the effect metformin had on the subcellular location of 
PGC-1α.  In the whole cell, PGC-1α’s expression was decreased in diabetes and 
recovered in metformin treated hearts.  Interestingly, following subcellular 
fractionation, the cytoplasmic fraction displayed no difference in PGC-1α 
expression following metformin treatment but unexpectedly PGC-1α expression was 
decreased in the nuclear extract of the same hearts. 
 This was somewhat surprising as the literature suggests that PGC-1α is 
active when transported into the nucleus [32].   A possible explanation could be that 
the PGC-1α double banding seen in the nuclear and whole cell homogenates could 
represent a post-translational process as suggested by other authors [31]. Based on 
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this the results are intriguing and difficult to interpret, but for sure they indicate 
trafficking of PGC-1α between the cell compartments following metformin treatment. 
However, a thorough investigation is needed in order to assess its functional state in these 
compartments by measuring the acetylation and phosphorylation of the protein. 
Intriguingly, very recent evidence suggests that PGC-1α can also reside directly in the 
mitochondria [31] and on activation potentially stimulates target genes directly within the 
mitochondria, thereby strengthening a direct link to mitochondrial biogenesis. 
Interestingly, AMPK phosphorylation following metformin administration was shown to 
improve mitochondrial biogenesis by inducing PGC-1α transcription in skeletal muscle 
[15], or by direct activation of PGC-1α by phosphorylation [51] suggesting a dual 
effector system following metformin treatment.  
 There has been a recent emergence in evidence that proteins that are crucial in 
mitochondrial dynamics namely Mfn-2, can also regulate mitochondrial metabolism [18]. 
Mfn-2 has pleiotropic roles within the cellular system, and has emerged as a key target of 
the PGC-1α regulatory pathway [52]. Soriano et al, 2006 showed that overexpression of 
PGC-1α in cultured muscle cells induced both Mfn-2 mRNA and protein expression 
above the levels of other genes typically enhanced by PGC-1α. They also found that 
PGC-1α stimulates the expression of Mfn-2 through its transcriptional properties [53]. 
Taking these findings alongside data showing that type 2 diabetes patients have a 
decreased expression of Mfn-2 in skeletal muscle [54] we hypothesised that if metformin 
administration can increase PGC-1α expression and improve mitochondrial organisation 
and appearance, Mfn-2 could be a link in the puzzle. However, we could not see a 
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significant reduction in Mfn-2 levels in the diabetic heart, yet interestingly; following 
metformin treatment Mfn-2 expression is greatly enhanced. 
 Nevertheless there are limitations to this study.  The chronic administration 
of metformin was performed in vivo for 4 weeks followed by infarct size 
determination conducted in ex vivo isolated heart preparations. Therefore our data 
revealed a direct effect of metformin on the cardiac tissue, without the influence of 
the whole body system which may occur in an in vivo model of ischemia reperfusion 
injury.  Our molecular investigations were limited to whole heart tissue; however, 
the effect of metformin on the regulation of PGC-1α needs to be investigated in 
further studies using cellular and molecular models.  
 
Conclusions 
In co-morbidities such as old age and diabetes, cardiomyocytes’ mitochondrial 
respiration and metabolism are thought to be affected [55]. Our results suggest that 
chronic metformin treatment can be cardioprotective by improving mitochondrial 
biogenesis in the diabetic heart. This could be achieved via a pathway involving 
AMPK/PGC-1α/Mfn-2; a pathway that certainly warrants further investigation. 
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Tables 
 
Table 1 
 Goto Kakizaki - Control Goto Kakizaki -Metformin  
Measurement Initial 2weeks 4weeks Initial 2weeks 4weeks 
Body mass (g) 439.7 ± 8.2 436.4 ± 8.5 432.4 ± 7.9 461.4 ± 8.4 431.9 ± 6.7* 427.1 ± 
7.1** 
Heart mass(g) - - 2.77 ± 0.07 - - 2.66 ± 0.08 
Blood Glucose 
(mmol/L) 
12.4 ± 0.8 10.5 ± 0.6 11.8 ± 0.9 15.5 ± 1.6 9.7 ± 0.4 10.3 ± 0.5** 
HbA1c 
(mmol/mol) 
67.6 ± 3.3 - 61.4 ± 3.7 58.2 ± 5.2 - 44.3 ± 3.4* 
 
Table 1: Summary of parameters measured before, during and after administration 
of water +non-caloric sweetener or 300mg/kg/day metformin in water + non-caloric 
sweetener. Body mass, blood glucose and HbA1c were measured initially, at 2 weeks 
and at 4 weeks prior to excision of the heart for experimentation. Heart mass was 
measured following isolated Langendorff heart preparation. Data is represented as mean 
± S.E.M, n≥6. *P<0.05 versus initial reading within group. **P<0.005 versus initial 
reading within group. Repeated measures ANOVA was used to determine statistical 
significance. 
 
Table 2 
 Wistar - Control Wistar -Metformin 
Measurement Initial 2weeks 4weeks Initial 2weeks 4weeks 
Body mass (g) 573.1 ± 
14.1 
550.3 ± 
14.3 
544.5 ± 13.9 553.6 ± 26.1 543.3 ± 23.7 549.1 ± 29.1 
Heart mass(g) - - 1.85 ± 0.06 - - 1.90 ± 0.08 
Blood Glucose 
(mmol/L) 
7.5 ± 0.2 7.0 ± 0.4 6.8 ± 0.9 7.6 ± 0.4 7.1 ± 0.3 7.5 ± 0.5 
HbA1c 
(mmol/mol) 
26.6 ± 0.6 - 25.7 ± 1.6 27.9 ± 1.2 - 24.3 ± 0.7 
 
Table 2: Summary of parameters measured before, during and after administration 
of water +non-caloric sweetener or 300mg/kg/day metformin in water + non-caloric 
sweetener. Body mass, blood glucose and HbA1c were measured initially, at 2 weeks 
and at 4 weeks prior to excision of the heart for experimentation. Heart mass was 
measured following isolated Langendorff heart preparation. Data is represented as mean 
± S.E.M, n≥6. Repeated measures ANOVA was used to determine statistical significance. 
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Figure legends 
 
Figure 1: The effect of chronic metformin on infarct size and cardiac function in 
the GK rat a. Infarct size is expressed as the infarcted volume within the area at risk 
of the left ventricle (% I/R) in hearts either treated with metformin for 4 weeks or 
control hearts. Chronic metformin significantly reduced the infarct size compared to 
the control group. Data is shown as mean ± S.E.M, n≥6. *** P<0.0001 versus control; 
b. Rate pressure product (RPP) was calculated as HR x LVDP; c. Coronary flow, no 
significant differences were seen following metformin treatment. White circles= non-
treated Goto Kakizaki, Black squares = metformin-treated Goto Kakizaki. Student’s t-
test was used for statistical analysis. 
 
Figure 2: The effect of chronic metformin on infarct size and cardiac function in 
the Wistar rat a. Infarct size is expressed as the infarcted volume within the area at 
risk of the left ventricle (% I/R) in hearts either treated with metformin for 4 weeks or 
control hearts. Chronic metformin significantly reduced the infarct size compared to 
the control group. Data is shown as mean ± S.E.M, n≥6. * P<0.05 versus control; b. 
Rate pressure product (RPP) was calculated as HR x LVDP; c. Coronary flow, no 
significant differences were seen following metformin treatment. White circles= non-
treated Wistar, Black squares = metformin-treated Wistar. Student’s t-test was used 
for statistical analysis. 
 
 
Figure 3: Chronic metformin treatment leads to mitochondrial appearance in 
the diabetic heart to become more like that of Wistar hearts. a. Non treated 12 
month old Goto Kakizaki diabetic heart. b. Metformin treated (4 weeks 
300mg/kg/day) Goto Kakizaki diabetic heart. c. 12 month old Wistar 
normoglycaemic heart. (Representative electron micrograph photos) 
 
Figure 4: The effect of chronic metformin treatment on AMPK and Akt level 
and phosphorylation. a. Metformin increases AMPK phosphorylation but has no 
effect on AMPK’s total levels in Goto Kakizaki (GK) rat hearts. Data is shown as 
mean ± S.E.M, n=4 per group. *P<0.05 **P<0.005 versus non-treated GK. b. Akt 
total level and activation are unaffected following 4 weeks metformin treatment. Data 
is shown as mean ± S.E.M, n=4 per group. One-way ANOVA followed by 
Bonferroni’s multiple comparison test were used to determine statistical significance. 
 
Figure 5: Chronic metformin treatment increases PGC-1α and Mfn-2 
expression. a. PGC-1α protein expression is decreased in myocardial tissue of type II 
diabetic rats compared to non-diabetic Wistar rat hearts. Following chronic 
metformin treatment PGC-1α expression is increased. Data is shown as mean ± 
S.E.M, n=4 per group. *P<0.05 ***P<0.0005 versus non treated GK. Densitometric 
results express the sum of two representative bands of PGC-1α protein. b. Mfn-2 
expression did not significantly differ between diabetic and non-diabetic heart tissue. 
Chronic metformin treatment increased the expression of Mfn-2. Data is shown as 
mean ± S.E.M, n=4 per group. *P<0.05 **P<0.005 versus treated GK. One-way 
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ANOVA followed by Bonferroni’s multiple comparison test were used to determine 
statistical significance. 
 
Figure 6: Chronic metformin treatment leads to decreased nuclear accumulation 
of PGC-1α. Following metformin treatment, PGC-1α expression in the nuclear 
fragment decreased compared to that of the non-treated Goto Kakizaki. Data is shown 
as mean ± S.E.M, n=4 per group, **P<0.005. PGC-1α expression is calculated by 
measuring both bands and corrected to the nuclear loading control TATA. Student’s 
t-test was used for statistical analysis. 
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Figure 4 
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Figure 5 
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